CRISPR Therapeutics (NasdaqGM:CRSP) has set new 2026 milestones, including planned regulatory submissions for Casgevy in ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is among the Growth Stock Portfolio: 12 Stock Picks By Cathie Wood. On January 22, 2026, ...

Last year, a ten-month-old baby in the US was the first person in the world to have their rare genetic disease effectively ...

Scientists used CRISPR technology to disable the cholesterol gene in a groundbreaking study, though widespread availability ...

The hold followed Intellia’s voluntary pause in response to a grade 4 liver event—a case of Hy’s Law—in the ATTR-CM trial.

In November 2023, the UK became the first country in the world to authorise a Crispr gene-editing therapy.

What if a cup of coffee could help treat cancer? Researchers at the Texas A&M Health Institute of Biosciences and Technology ...

When it was announced in 2023 that the world’s first Crispr-based gene-editing therapy had been approved in the UK there was ...

Artificial intelligence (AI) isn't the only industry with explosive growth potential.

Explore groundbreaking gene-editing therapy for kidney disease, offering hope to those with polycystic kidney disease.

A new CRISPR-based one-off procedure that lowers "bad" cholesterol has been approved to enter Phase I human trial. If ...

Why CRISPR Therapeutics Is On Investors’ Radar Today CRISPR Therapeutics (CRSP) has attracted fresh attention after recent trading left the stock around $54.65, with performance mixed over the past ...